Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05432713
Other study ID # LP-168-CN102
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date May 14, 2022
Est. completion date December 28, 2022

Study information

Verified date February 2023
Source Guangzhou Lupeng Pharmaceutical Company LTD.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a Phase I study designed to assess the safety, tolerability and pharmacokinetics of LP-168 in healthy human volunteers.


Description:

This study will enroll 70 healthy subjects, will set 4 SAD and 3 MAD dose cohorts, with 10 subjects in each dose cohort. Subjects will be assigned to L-168 or placebo group by ratio of 8:2 in each cohort. Sentinel subjects will be used in each dose cohort during the single dose phase.


Recruitment information / eligibility

Status Completed
Enrollment 70
Est. completion date December 28, 2022
Est. primary completion date November 20, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 55 Years
Eligibility Inclusion Criteria: - Subjects have no history of serious digestive system, central nervous system, cardiovascular system, kidney, respiratory system, metabolism and endocrine, skeletal and muscular system, blood system disease and cancer - Subjects (including partners) are willing to take effective contraception measures during study and within 3 months after last dose - Male and female healthy subjects aged 18 to 55 years old - Male subjects weigh = 50 kg, and female subjects weigh = 45 kg - Subjects able to understand and comply with study requirements - Willing to sign the informed consent Exclusion Criteria: - Abnormal vital signs, physical examination or laboratory tests with clinical significance - Abnormal ECG or echocardiography with clinical significance - Hepatitis B virus, Hepatitis C virus, HIV and syphilis test positive. COVID-19 DNA positive. - Subjects who have taken any drugs or health care products within 14 or 28 days before administration the study drug - Subjects who have consumed diets that may alter the activity of liver metabolic enzymes within 7 days before administration the study drug - Subjects who have consumed tea or alcohol-containing food product within 24hrs before administration the study drug - Subjects who have a history of dysphagia or condition may affect drug absorption, distribution, metabolism and excretion - Female subjects are breastfeeding or pregnant - Subjects who have a history of drug/ alcohol/ tobacco abuse - Subjects who have had a blood donation or massive blood loss within three months before screening; or had surgery within six months before screening - Subjects who have participated in other clinical trial within three months before screening - Subjects have special dietary requirements or cannot tolerate a standard meal

Study Design


Intervention

Drug:
LP-168 tablet
Lp-168 is a small molecule kinase inhibitor that is administered once daily via oral administration
LP-168 Placebo tablet
LP-168 placebo tablets contain excipients for LP-168 tablets, but do not contain the active ingredients of the drug, and are used for comparison in clinical trials with the same usage and dosage as LP-168 tablets

Locations

Country Name City State
China The Second Affiliated Hospital Zhejiang University School of Medicine Hangzhou Zhejiang

Sponsors (1)

Lead Sponsor Collaborator
Guangzhou Lupeng Pharmaceutical Company LTD.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants With Treatment Emergent Adverse Events as determined by CTCAE v5.0 From the first dose of the study drug to 5 days after last dose
Primary Severity of Treatment Emergent Adverse Events as determined by CTCAE v5.0 From the first dose of the study drug to 5 days after last dose
Primary Pharmacokinetics (PK) As Assessed By Maximum Observed Plasma Concentration (Cmax) of LP-168 Up to 96 hours post last dose
Primary PK As Assessed By Area Under The Plasma Concentration Time Curve From Time 0 To The Time of The Last Quantifiable Concentration (AUC0-t) Of LP-168 Up to 96 hours post last dose
Primary PK As Assessed By Time To Maximum Observed Plasma Concentration (Tmax) of LP-168 Up to 96 hours post last dose
Primary PK As Assessed By Terminal Half-life (t1/2) of LP-168 Up to 96 hours post last dose
Primary PK As Assessed By Terminal Vd/F of LP-168 Up to 96 hours post last dose
Primary PK As Assessed By Terminal CL/F of LP-168 Up to 96 hours post last dose
Secondary PD as Assessed by elisa analysis the proportion of LP-168 occupied kinase at scheduled timepoints pre-dose and post-dose Up to 48 hours post last dose
See also
  Status Clinical Trial Phase
Completed NCT05528666 - Risk Perception in Multiple Sclerosis
Completed NCT03608527 - Adaptive Plasticity Following Rehabilitation in Multiple Sclerosis N/A
Recruiting NCT05532943 - Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With Multiple Sclerosis Phase 1/Phase 2
Completed NCT02486640 - Evaluation of Potential Predictors of Adherence by Investigating a Representative Cohort of Multiple Sclerosis (MS) Patients in Germany Treated With Betaferon
Completed NCT01324232 - Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis Phase 2
Completed NCT04546698 - 5-HT7 Receptor Implication in Inflammatory Mechanisms in Multiple Sclerosis
Active, not recruiting NCT04380220 - Coagulation/Complement Activation and Cerebral Hypoperfusion in Relapsing-remitting Multiple Sclerosis
Completed NCT02835677 - Integrating Caregiver Support Into MS Care N/A
Completed NCT03686826 - Feasibility and Reliability of Multimodal Evoked Potentials
Recruiting NCT05964829 - Impact of the Cionic Neural Sleeve on Mobility in Multiple Sclerosis N/A
Withdrawn NCT06021561 - Orofacial Pain in Multiple Sclerosis
Completed NCT03653585 - Cortical Lesions in Patients With Multiple Sclerosis
Recruiting NCT04798651 - Pathogenicity of B and CD4 T Cell Subsets in Multiple Sclerosis N/A
Active, not recruiting NCT05054140 - Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis Phase 2
Completed NCT05447143 - Effect of Home Exercise Program on Various Parameters in Patients With Multiple Sclerosis N/A
Recruiting NCT06195644 - Effect of Galvanic Vestibular Stimulation on Cortical Excitability and Hand Dexterity in Multiple Sclerosis Patients Phase 1
Completed NCT04147052 - iSLEEPms: An Internet-Delivered Intervention for Sleep Disturbance in Multiple Sclerosis N/A
Completed NCT03591809 - Combined Exercise Training in Patients With Multiple Sclerosis N/A
Completed NCT03594357 - Cognitive Functions in Patients With Multiple Sclerosis
Completed NCT02845635 - MS Mosaic: A Longitudinal Research Study on Multiple Sclerosis